Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 776,133 | 825,410 | 745,145 | 747,313 | 745,740 |
| Cost of Goods | 140,085 | 150,090 | 151,558 | 136,139 | 188,457 |
| Gross Profit | 636,048 | 675,320 | 593,587 | 611,174 | 557,283 |
| Operating Expenses | 682,825 | 398,523 | 370,252 | 449,906 | 443,847 |
| Operating Income | -46,692 | 276,887 | 223,893 | 161,407 | 113,893 |
| Interest Expense | 2,579 | 2,679 | 2,863 | 2,577 | 2,968 |
| Other Income | 22,947 | 23,660 | 17,059 | 10,809 | 23,516 |
| Pre-tax Income | -26,324 | 297,868 | 238,089 | 169,639 | 134,441 |
| Income Tax | 4,420 | 57,336 | 52,403 | 44,696 | 28,361 |
| Net Income Continuous | -30,744 | 240,532 | 185,686 | 124,943 | 106,080 |
| Net Income | $-30,744 | $240,532 | $185,686 | $124,943 | $106,080 |
| EPS Basic Total Ops | -0.16 | 1.25 | 0.97 | 0.66 | 0.56 |
| EPS Basic Continuous Ops | -0.16 | 1.25 | 0.97 | 0.66 | 0.56 |
| EPS Diluted Total Ops | -0.16 | 1.23 | 0.95 | 0.65 | 0.55 |
| EPS Diluted Continuous Ops | -0.16 | 1.22 | 0.95 | 0.65 | 0.54 |
| EPS Diluted Before Non-Recurring Items | -0.08 | 1.25 | 0.98 | 0.72 | 0.74 |
| EBITDA(a) | $-29,183 | $294,095 | $244,600 | $183,288 | $130,958 |